MBX Biosciences appoints Steven Hoerter as CEO, John Smither as CFO; CEO Hawryluk departs

MBX Biosciences, Inc.

CEO Kent Hawryluk steps down July 13, 2026; will advise through Aug 16, 2026 under consulting agreement.
Steven Hoerter, former executive Chairman, appointed President and CEO effective July 13, 2026; base salary $665k, target bonus 60%.
John Smither, interim CFO, appointed CFO effective July 13, 2026; base salary $530k, target bonus 40%, plus $150k relocation bonus.
New CEO receives 331k stock options and 71k RSUs; new CFO receives 130k options and 28k RSUs, both with 4-year vesting.
Hawryluk's separation includes 12 months severance, COBRA, target bonus, and accelerated equity vesting through Aug 16, 2027.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kent P. Hawryluk

Chief Executive Officer

MBX · MBX Biosciences, Inc.

Effective: 2026-07-13
Successor: Steven Hoerter
Filed: July 13, 2026, 4:46 PM ET

Departure of Chief Executive Officer Kent P. Hawryluk will be stepping away from his role as the Company’s Chief Executive Officer and end his services as a member of the Board effective as of July 13, 2026.

Appointed

Steven Hoerter

President and Chief Executive Officer

MBX · MBX Biosciences, Inc.

Effective: 2026-07-13
Filed: July 13, 2026, 4:46 PM ET

On July 9, 2026, the Board appointed Steven Hoerter, the Company’s current executive Chairman of the Board, as President and Chief Executive Officer and principal executive officer of the Company, effective as of July 13, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kent P. Hawryluk departed as Chief Executive Officer at MBX Biosciences, Inc..

Action: stepped down
Role: Chief Executive Officer

Exact text from the filing

Departure of Chief Executive Officer Kent P. Hawryluk will be stepping away from his role as the Company’s Chief Executive Officer and end his services as a member of the Board effective as of July 13, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Hoerter was appointed as President and Chief Executive Officer at MBX Biosciences, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On July 9, 2026, the Board appointed Steven Hoerter, the Company’s current executive Chairman of the Board, as President and Chief Executive Officer and principal executive officer of the Company, effective as of July 13, 2026.

View on SEC.gov

MBX Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-302098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.